NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Transocean Ltd. (NYSE:RIG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transocean-ltd-lawsuit-submission-form?prid=129474&wire=1 or contact Joseph E.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your MGP Ingredients, Inc. (NASDAQ:MGPI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/mgp-ingredients-inc-lawsuit-submission-form?prid=129488&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Nextracker Inc. (NASDAQ:NXT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/nextracker-inc-lawsuit-submission-form?prid=129464&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Innovative Industrial Properties, Inc. (NYSE:IIPR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/innovative-industrial-properties-inc-lawsuit-submission-form?prid=129465&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your TELUS International (Cda) Inc. (NYSE:TIXT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/telus-international-lawsuit-submission-form?prid=129466&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Elastic N.V. (NYSE:ESTC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/elastic-n-v-lawsuit-submission-form?prid=129469&wire=1 or contact Joseph E.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Crocs, Inc. (NASDAQ:CROX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/crocs-inc-lawsuit-submission-form?prid=129470&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129471&wire=1 or contact Joseph E. Levi, Esq.

The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA) Philadelphia, Pennsylvania--(Newsfile Corp. - February 14, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003), which is currently underway in nine (9) clinical sites in United States, has now randomized more than 50% of the 60 patients expected to be enrolled in the study.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Capri Holdings Limited (NYSE:CPRI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/capri-holdings-lawsuit-submission-form?prid=129467&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Joint Stock Company Kaspi.kz (NASDAQ:KSPI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/joint-stock-company-kaspi-kz-lawsuit-submission-form?prid=129468&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Constellation Brands, Inc. ("Constellation Brands, Inc.") (NYSE:STZ) concerning possible violations of federal securities laws. On January 10, 2025, Constellation issued a press release announcing the company's third quarter fiscal year 2025 results, showcasing a significant miss on sales performance in the Beer segment and an even steeper miss for the Wine & Spirits segment.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agilysys, Inc. ("Agilysys, Inc.") (NASDAQ:AGYS) concerning possible violations of federal securities laws. On January 21, 2025, Agilysys issued a press release announcing third quarter revenue below expectations and the company's own guidance, resulting in a significant revision to Agilysys' FY25 revenue guidance.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Universal Display Corporation ("Universal Display Corporation") (NASDAQ:OLED) concerning possible violations of federal securities laws. On August 1, 2024, Universal reported solid 2Q 2024 results and raised the bottom-end of its full year revenue outlook.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=129472&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=129473&wire=1 or contact Joseph E. Levi, Esq.

Montclair, NJ, Feb. 14, 2025 (GLOBE NEWSWIRE) -- 180 Degree Capital Corp. (NASDAQ:TURN) today issued the following Q4 2024 Shareholder Letter:

NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or the “Company”), announced that data from its US and UK conducted first-in-human dose escalation clinical study (“Western study”) of CRB-701 (SYS6002) is being presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Triumph Financial, Inc. ("Triumph Financial, Inc.") (NASDAQ:TFIN) concerning possible violations of federal securities laws. On January 22, 2025, after market close, Triumph published a quarterly earnings report stating that it had a profit of $0.13 per share, missing the Zacks Consensus Estimate of $0.26 per share by 50%.